ChromaDex (CDXC) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ChromaDex Reports 2016 Record Revenue as Ingredient Sales Grew 34%
March 16, 2017 4:10 PM EDTIRVINE, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today the financial results for the year ended Dec. 31, 2016.
We finished 2016 on a strong note, generating 29% year over year revenue growth during the fourth quarter, commented Frank Jaksch, Jr., CEO and co-founder of ChromaDex. We achieved record full year revenue of $26.8 million in 2016, driven by continued adoption of NIAGEN® branded nicotinamide riboside (NR).... More
